 Connection
Patrick Johnston to Recombinant Proteins
This is a "connection" page, showing publications Patrick Johnston has written about Recombinant Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.149 |
|
|
|
-
Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol. 2016 Jul; 3(7):e309-16.
Score: 0.096
-
Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE. A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant. 2017 Oct; 52(10):1372-1377.
Score: 0.026
-
Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct; 92(10):1004-1010.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|